The purpose of this study is to assess the immediate and long-term safety and efficacy of on-demand treatment of patients with severe hemophilia A using recombinant factor VIII SQ (r-VIII SQ) over a one year period. Objective and subjective assessments of the product will be based on patient outcome, laboratory values, adverse event reports and the investigator's and patient's judgements.
Showing the most recent 10 out of 782 publications